
Aditxt, Inc. Common Stock
ADTX
ADTX: Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes a tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.
moreShow ADTX Financials
Recent trades of ADTX by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ADTX's directors and management
Government lobbying spending instances
-
$40,000 Jul 18, 2022 Issue: Health Issues
-
$60,000 Apr 19, 2022 Issue: Health Issues
-
$20,000 Jan 18, 2022 Issue: Health Issues
New patents grants
Federal grants, loans, and purchases
Followers on ADTX's company Twitter account
Number of mentions of ADTX in WallStreetBets Daily Discussion
Recent insights relating to ADTX
Recent picks made for ADTX stock on CNBC
ETFs with the largest estimated holdings in ADTX
Flights by private jets registered to ADTX